Global Prostate Cancer Diagnostics Market Expected To Achieve A Sustainable Grow

Posted by Arslan on August 27th, 2019

In order to dissert the market scenario prevailing across the prostate cancer diagnostics market sector, Fact.MR has evenly presented a comprehensive analysis report on prostate cancer diagnostics market to its extensive online repository. With all vital market facets enclosed into this single assessment, readers can learn about different market drivers, opportunities and trends which are likely to influence the overall market space for the prostate cancer diagnostics market in the coming years. In addition, factors such as market size, Y-o-Y growth and revenue share are investigated so as to make this research highly authentic and reliable.

The PCA3 and PSA test segments can be considered the most important in the prostate cancer diagnostics market as they both represent the highest potential in terms of market opportunity. The PSA segment is anticipated to be worth just over US$ 270 million in 2017 and it should grow at a healthy CAGR during the period 2017-2022. On the other hand, the PCA3 segment is poised to grow to nearly US$ 284 million by the end of the forecast period. North America is the largest region for both segments and accounts for nearly 2/5^th of the prostate cancer diagnostics market. The region’s large geriatric population and high prevalence of cancer mean that demand for prostate cancer diagnostics will continue to remain strong during the forecast period.

The CTC segment holds revenue share in the global prostate cancer diagnostics market. This segment is projected to reach US$ 141 million by the end of 2022. The immunohistochemistry segment is projected to witness a CAGR of 4.5% for the five-year study period. While North America may be the largest regional contributor, key stakeholders could also focus on Europe as it holds a revenue share of more than 30% throughout the period.

Focus on Hospital Labs and Research Institutes

The hospital associated labs segment is assessed to grow significantly during the forecast period. It would make sense for companies to focus on cancer research institutes as collaboration can help in the development of innovative solutions. In this case, companies could think of targeting the APEJ region as it has the highest CAGR during the forecast period. The region spends much less on healthcare as a percentage of GDP than the developed world but strong economic growth will all but ensure that it becomes ever-more important to regional governments in future.

Key players in the global market for prostate cancer diagnostics include Abbott Laboratories, Biocept, Inc., AstraZeneca plc., Cancer Genetics, Inc., Danaher Corporation, Bayer Aktiengesellschaft, Becton, Dickinson and Company, Agilent Technologies, Foundation Medicine, Inc., and Myriad Genetics Inc.

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=58

Table of Content:

Chapter 1. Global Prostate Cancer Diagnostics Market - Executive Summary. 11

Chapter 2. Global Prostate Cancer Diagnostics Market Overview. 13

2.1. Introduction. 13

       2.1.1. Global Prostate Cancer Diagnostics Market Taxonomy. 13

       2.1.2. Global Prostate Cancer Diagnostics Market Definition. 13

2.2. Global Prostate Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 14

       2.2.1. Global Prostate Cancer Diagnostics Market Y-o-Y Growth. 14

2.3. Global Prostate Cancer Diagnostics Market Dynamics. 14

       2.3.1. Drivers. 14

Continued…………………